Evaluation and management of chemotherapy-induced cardiotoxicity in breast cancer: a Delphi study

Clinical and Translational Oncology

Volumn 19, Issue 1, 2017, Pages 91-104

  Gavila, J ^a   Segui M A ^b   Calvo, L ^c   Lopez T ^d   Alonso, J J ^e   Farto, M ^f   Sanchez de la Rosa R ^f  

^a INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^b Servicio de Oncología Médica   (Spain)

^c HOSPITAL JUAN CANALEJO   (Spain)

^d HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^e HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

^f TEVA PHARMACEUTICALS   (Israel)

Author keywords

Anthracycline; Breast cancer; Cardiotoxicity; Delphi study; Trastuzumab

Indexed keywords

ANTHRACYCLINE; TAXANE DERIVATIVE; TRASTUZUMAB; ANTINEOPLASTIC AGENT;

ARTICLE; BREAST CANCER; CANCER THERAPY; CHEMOTHERAPY INDUCED CARDIOTOXICITY; CLINICAL OUTCOME; CLINICAL TRIAL (TOPIC); DELPHI STUDY; DRUG INDUCED DISEASE; ECHOCARDIOGRAPHY; FEMALE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MULTICENTER STUDY; RISK FACTOR; AGED; BREAST NEOPLASMS; CANCER STAGING; CARDIOTOXICITY; DRUG EFFECTS; EVALUATION STUDY; FOLLOW UP; HEART LEFT VENTRICLE FUNCTION; PROGNOSIS;

AGED; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARDIOTOXICITY; DELPHI TECHNIQUE; FEMALE; FOLLOW-UP STUDIES; HUMANS; NEOPLASM STAGING; PROGNOSIS; RISK FACTORS; VENTRICULAR FUNCTION, LEFT;

EID: 84971671146     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-016-1508-y     Document Type: Article

References (43)

1. Breast cancer: prevention and control. World Health Organization. 2012. http://www.who.int/cancer/detection/breastcancer/en/index1.html.
2. Berry D, Cronin K, Plevritis S, Fryback D, Clarke L, Zelen M, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353:1784–92.
3. Minotti G. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004;56:185–229.
4. Brana I, Tabernero J. Cardiotoxicity. Ann Oncol. 2010;21:173–9.
5. Jones LW, Haykowsky MJ, Swartz JJ, Douglas PS, McKey JR. Early breast cancer: therapy and cardiovascular injury. J Am Coll Cardiol. 2007;50:1435–41.
6. Jones RL, Ewer MS. Cardiac and cardiovascular toxicity of nonanthracycline anticancer drugs. Expert Rev Anticancer Ther. 2006;6:1249–69.
7. Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet. 2007;370:2011–9.
8. Jiji RS, Kramer CM, Salerno M. Non-invasive imaging and monitoring cardiotoxicity of cancer therapeutic drugs. J Nucl Cardiol. 2012;19:377–88.
9. Barrett-Lee PJ, Dixon JM, Farrell C, Jones A, Leonard R, Murray N, et al. Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk. Ann Oncol. 2009;20:816–27.
10. Ng R, Better N, Green MD. Anticancer agents and cardiotoxicity. Semin Oncol. 2006;33:2–14.
11. Guo S, Wong S. Cardiovascular toxicities from systemic breast cancer therapy. Front Oncol. 2014;4:1–10.
12. Curigliano G, Cardinale D, Suter T, Plataniotis G, de Azambuja E, Sandri MT, et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol. 2012;23:155–66.
13. Eschenhagen T, Force T, Ewer M, de Keulenaer GW, Suter TM, Anker SD, et al. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2011;13:1–10.
14. Ky B, Putt M, Sawaya H, French B, Januzzi JL, Sebag IA, et al. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes and trastuzumab. J Am Coll Cardiol. 2014;63:809–16.
15. Graham B, Regehr G, Wright JG. Delphi as a method to establish consensus for diagnostic criteria. J Clin Epidemiol. 2003;56:1150–6.
16. National Cancer Institute. Cancer therapy evaluation program. 2012. http://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcv20_4e30e992.pdf.
17. Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Sherrer-Corbie M, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014;27:911–39.
18. Barco S, Ciruelos E, Tusquets I, Ruiz M, Barhadas A. SEOM Clinical Guidelines for the systemic treatment of early breast cancer 2013. Clin Transl Oncol. 2013;15:1011–7.
19. Llombart A, Haba J, Ruiz-Simón A, Álvarez-López I, Cortés J. SEOM Clinical Guidelines for the management of metastatic breast cancer. Clin Transl Oncol. 2013;15:1004–10.
20. Ganz PA, Hussey MA, Moinpour CM, Unger JM, Hutchins LF, Dahkil SR, et al. Late cardiac effects of adjuvant chemotherapy in breast cancer survivors treated on Southwest Oncology Group protocol s8897. J Clin Oncol. 2008;26:1223–30.
21. Hershman DL, McBride RB, Eisenberger A, Tsai WY, Grann VR, Jacobson JS. Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin’s lymphoma. J Clin Oncol. 2008;26:3159–65.
22. Gianni L, Herman EH, Lipshultz SE, Minotti G, Sarvazyan N, Sawyer DB. Anthracycline cardiotoxicity: from bench to bedside. J Clin Oncol. 2008;26:3777–84.
23. Chien AJ, Rugo HS. The cardiac safety of trastuzumab in the treatment of breast cancer. Expert Opin Drug Saf. 2010;9:335–46.
24. Suter TM, Procter M, van Veldhuisen DJ, Muscholl M, Bergh J, Carlomagno C, et al. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol. 2007;25:3859–65.
25. Colombo A, Cipolla C, Beggiato M, Cardinale D. Cardiac toxicity of anticancer agents. Curr Cardiol Rep. 2013;15:1–11.
26. Hung MC, Lau YK. Basic science of HER-2/neu: a review. Semin Oncol. 1999;26:51–9.
27. Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozenweig M, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979;91:710–7.
28. Salvatorelli E, Menna P, Minotti G. Managing anthracycline-induced cardiotoxicity: beginning with the end in mind. Future Cardiol. 2015;11:363–6.
29. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Eng J Med. 2001;344:783–92.
30. Romond EH, Jeong J-H, Rastogi P, Swain SM, Geyer CE Jr, Ewens MS, et al. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2012;30:3792–9.
31. Goethals I, De Winter O, De Bondt P, De Sutter J, Dierckx R, Van de Wiele C, et al. The clinical value of nuclear medicine in the assessment of irradiation-induced and anthracycline-associated cardiac damage. Ann Oncol. 2002;13:1331–9.
32. Von Hoff DD, Rozencweig M, Piccart M. The cardiotoxicity of anticancer agents. Semin Oncol. 1982;9:23–33.
33. Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002;20:1215–21.
34. Jurcut R, Wildiers H, Ganame J, D’hooge J, Paridaens R, Voigt JU et al. Detection and monitoring of cardiotoxicity—what does modern cardiology offer? Support Care Cancer. 2008;16:437–45.
35. Mitani I, Jain D, Joska TM, Burtness B, Zaret BL. Doxorubicin cardiotoxicity: prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era. J Nucl Cardiol. 2003;10:132–9.
36. Tian S, Hirshfield KM, Jabbour S, Toppmeyer D, Haffty BG, Khan AJ, et al. Serum biomarkers for the detection of cardiac toxicity after chemotherapy and radiation therapy in breast cancer patients. Front Oncol. 2014;4:1–14.
37. Genetech, Inc. Package insert, herceptin (trastuzumab). Food and Drug Administration. 2003. http://www.accessdata.fd.gov/drugsatfda_docs/label/2000/trasgen020900lb.htm. Accessed 30 July 2013.
38. Schwartz RG, McKenzie WB, Alexander J, Sager P, D’Souza A, Mantunga A, et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy: seven-year experience using serial radionuclide angiocardiography. Am J Med. 1987;82:1109–18.
39. Vogel C, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Ferenbacher L, et al. Efficacy and safety of trastuzumab as single agent first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20:719–26.
40. Giotta F, Lorusso V, Maiello E, Filippelli G, Valerio MR, Caruso M, et al. Liposomal-encapsulated doxorubicin plus cyclophosphamide as first-line therapy in metastatic breast cancer: a phase II multicentric study. Ann Oncol. 2007;18(Suppl 6):vi66–9.
41. O’Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoso A, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 2004;15:440–9.
42. Harris L, Batist G, Belt R, Rovira D, Navari R, Azarnia N, et al. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer. 2002;94:25–36.
43. Batist G, Ramakrishnan G, Rao CS, Chandrasekharan A, Gutheil J, Guthrie T, et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol. 2001;19:1444–54.